{"id":3764,"date":"2026-06-05T09:28:44","date_gmt":"2026-06-05T16:28:44","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=3764"},"modified":"2026-06-05T09:28:46","modified_gmt":"2026-06-05T16:28:46","slug":"jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/","title":{"rendered":"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review."},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized\"><img fetchpriority=\"high\" decoding=\"async\" width=\"760\" height=\"715\" src=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png\" alt=\"Jiangsu Vcare\" class=\"wp-image-3766\" style=\"object-fit:contain;width:420px;height:310px\" srcset=\"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png 760w, https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1-300x282.png 300w, https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1-500x470.png 500w\" sizes=\"(max-width: 760px) 100vw, 760px\" \/><figcaption class=\"wp-element-caption\">Jiangsu Vcare<\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The drug&#8217;s New Drug Application (NDA) was formally accepted and subsequently approved by the NMPA via priority review and conditional approval mechanisms<a href=\"https:\/\/www.pharnexcloud.com\/zixun\/shiye\/spdt_94784\"><\/a><a href=\"https:\/\/bydrug.pharmcube.com\/news\/detail\/f2e4eaff8f12a8f5ec6b3024c2c20b86\"><\/a><a href=\"https:\/\/medicilon.com.cn\/khhd\/drug1412.shtml\"><\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">VC004 is the first approved Category 1 innovative chemical drug from Jiangsu Vcare PharmaTech. It is specifically designed for patients with refractory solid tumors harboring NTRK fusion genes, with its core advantage being the significant ability to overcome resistance to traditional targeted therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The drug is indicated for adults and adolescents aged 12 years and older: patients with locally advanced or metastatic solid tumors who have been tested and found to harbor NTRK fusion genes without known acquired resistance mutations, as well as those who are at high risk for surgical resection, have no satisfactory alternative therapy, or have failed prior treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Buy VC004&nbsp;online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The drug&#8217;s New Drug Application (NDA) was formally accepted and subsequently approved by the NMPA via priority review and conditional approval mechanisms. VC004 is the first approved Category 1 innovative chemical drug from Jiangsu Vcare PharmaTech. It is specifically designed for patients with refractory solid tumors harboring NTRK fusion genes, with its core advantage being [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":3766,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-3764","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China<\/title>\n<meta name=\"description\" content=\"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare\uff1avc004-injection-approved-via-priority-review\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare\uff1avc004-injection-approved-via-priority-review\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T16:28:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T16:28:46+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"760\" \/>\n\t<meta property=\"og:image:height\" content=\"715\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review.\",\"datePublished\":\"2026-06-05T16:28:44+00:00\",\"dateModified\":\"2026-06-05T16:28:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/\"},\"wordCount\":167,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png\",\"articleSection\":[\"Approved News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/\",\"name\":\"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png\",\"datePublished\":\"2026-06-05T16:28:44+00:00\",\"dateModified\":\"2026-06-05T16:28:46+00:00\",\"description\":\"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png\",\"width\":760,\"height\":715,\"caption\":\"Jiangsu Vcare\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China","description":"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare\uff1avc004-injection-approved-via-priority-review\/","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China","og_description":"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare\uff1avc004-injection-approved-via-priority-review\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-06-05T16:28:44+00:00","article_modified_time":"2026-06-05T16:28:46+00:00","og_image":[{"width":760,"height":715,"url":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png","type":"image\/png"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review.","datePublished":"2026-06-05T16:28:44+00:00","dateModified":"2026-06-05T16:28:46+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/"},"wordCount":167,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png","articleSection":["Approved News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/","url":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/","name":"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png","datePublished":"2026-06-05T16:28:44+00:00","dateModified":"2026-06-05T16:28:46+00:00","description":"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review. - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/c1821d7c-ce4a-4753-8c64-7710b72f4f0b-1.png","width":760,"height":715,"caption":"Jiangsu Vcare"},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/jiangsu-vcare%ef%bc%9avc004-injection-approved-via-priority-review\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Vcare\uff1aVC004\u00a0injection approved via priority review."}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=3764"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3764\/revisions"}],"predecessor-version":[{"id":3767,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3764\/revisions\/3767"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media\/3766"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=3764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=3764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=3764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}